2rgu

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:2rgu.jpg|left|200px]]
+
{{Seed}}
 +
[[Image:2rgu.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_2rgu| PDB=2rgu | SCENE= }}
{{STRUCTURE_2rgu| PDB=2rgu | SCENE= }}
-
'''Crystal structure of complex of human DPP4 and inhibitor'''
+
===Crystal structure of complex of human DPP4 and inhibitor===
-
==Overview==
+
<!--
-
A new chemical class of potent DPP-4 inhibitors structurally derived from the xanthine scaffold for the treatment of type 2 diabetes has been discovered and evaluated. Systematic structural variations have led to 1 (BI 1356), a highly potent, selective, long-acting, and orally active DPP-4 inhibitor that shows considerable blood glucose lowering in different animal species. 1 is currently undergoing clinical phase IIb trials and holds the potential for once-daily treatment of type 2 diabetics.
+
The line below this paragraph, {{ABSTRACT_PUBMED_18052023}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 18052023 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_18052023}}
==About this Structure==
==About this Structure==
Line 37: Line 41:
[[Category: Signal-anchor]]
[[Category: Signal-anchor]]
[[Category: Transmembrane]]
[[Category: Transmembrane]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 16:53:18 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Jul 29 15:07:11 2008''

Revision as of 12:07, 29 July 2008

Template:STRUCTURE 2rgu

Crystal structure of complex of human DPP4 and inhibitor

Template:ABSTRACT PUBMED 18052023

About this Structure

2RGU is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.

Reference

8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin -2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes., Eckhardt M, Langkopf E, Mark M, Tadayyon M, Thomas L, Nar H, Pfrengle W, Guth B, Lotz R, Sieger P, Fuchs H, Himmelsbach F, J Med Chem. 2007 Dec 27;50(26):6450-3. Epub 2007 Dec 1. PMID:18052023

Page seeded by OCA on Tue Jul 29 15:07:11 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools